Daiichi Sankyo’s Tumor Drug Meets Primary Endpoint in Late-Stage Study

, , , , , , , ,

Daiichi Sankyo announced that its Phase III ENLIVEN trial of pexidartinib met its primary endpoint.

Read more
/by